ArticleHaematologica2013
The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis.
Article in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- The emerging paradigms of SETD family enzymes as epigenetic regulators of the immune response in inflammatory diseases.Frontiers in immunology · 2026Review
- Identification and validation of a DNA methylation-driven gene-based prognostic model for clear cell renal cell carcinoma.BMC genomics · 2023Article
- A Computational Approach to Predict the Role of Genetic Alterations in Methyltransferase Histones Genes With Implications in Liver Cancer.Cancer informatics · 2023Article
- Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression.Cellular and molecular life sciences : CMLS · 2022Article
- SETD3 Methyltransferase Regulates PLK1 Expression to PromoteFrontiers in oncology · 2022Article
- The Structure, Activity, and Function of the SETD3 Protein Histidine Methyltransferase.Life (Basel, Switzerland) · 2021Review
- SVFX: a machine learning framework to quantify the pathogenicity of structural variants.Genome biology · 2020Article
- SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells.Scientific reports · 2020Article
- SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.BMC cancer · 2019Article
- CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth.Journal of experimental & clinical cancer research : CR · 2019Article
- SETD3 is a positive regulator of DNA-damage-induced apoptosis.Cell death & disease · 2019Article
- SETD3 protein is the actin-specific histidineeLife · 2018Article
- Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy.International journal of molecular sciences · 2018Review
- Phenotypic characterization of SETD3 knockout Drosophila.PloS one · 2018Article
- Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis.The Journal of biological chemistry · 2017Article
- Writing, erasing and reading histone lysine methylations.Experimental & molecular medicine · 2017Review
- Chromatin associated SETD3 negatively regulates VEGF expression.Scientific reports · 2016Article
- Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.Epigenetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
The SET domain is found in histone methyltransferases and other lysine methyltransferases. SET domain-containing proteins such as MLL1 play a critical role in leukemogenesis, while others such as SETD2 may function as a tumor suppressor in breast cancer and renal cell carcinoma. We recently discovered that SETD3, a well-conserved SET domain-containing protein, was involved in a translocation to the immunoglobulin lambda light chain locus in one of the non-homologous end-joining/p53-deficient peripheral B-cell lymphomas. We showed that a truncated mRNA lacking the SET domain sequences in Setd3 gene was highly expressed in the lymphoma. Furthermore, we found that the truncated SET-less protein displayed oncogenic potential while the full length SETD3 protein did not. Finally, SETD3 exhibits histone methyltransferases activity on nucleosomal histone 3 in a SET-domain dependent manner. We propose that this newly identified Setd3 gene may play an important role in carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.